Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of interleukin 23 neutralizing antibody in preparation of drug for endometriosis

A technology of interleukin and endometrium, which is applied in the field of application of interleukin-23 neutralizing antibodies in the preparation of endometriosis drugs, can solve the problems of poor treatment effect, easy disease recurrence, and intractable pathogenesis. Completely clear and other issues, to achieve the effect of inhibiting immune escape, enhancing the level, and reducing the size

Active Publication Date: 2018-08-10
NANJING DRUM TOWER HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the pathogenesis of EMS is not completely clear. Drug and surgical treatment are the main treatment measures at present, but the treatment effect is not good, and the disease is easy to relapse.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of interleukin 23 neutralizing antibody in preparation of drug for endometriosis
  • Application of interleukin 23 neutralizing antibody in preparation of drug for endometriosis
  • Application of interleukin 23 neutralizing antibody in preparation of drug for endometriosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] The level of IL-23 in peritoneal fluid from patients with endometriosis III-IV was analyzed.

[0024]According to the staging standard of endometriosis revised by the American Society for Reproductive Medicine in 1997: stage I (miniature) 1-5 points; stage II (mild) 6-15 points; stage III (medium) 16-40 points; stage IV (Heavy)>40 points. Clinically, patients with obvious symptoms such as dysmenorrhea, chronic pelvic pain, infertility, and requiring drug or surgical treatment are generally III-IV stage, so the research object of the present invention is mainly for III-IV endometriosis patients.

[0025] The collection of peritoneal fluid, endometrium and heterotopic lesions in the control group and EMS group were approved by the Ethics Committee of Drum Tower Hospital Affiliated to Nanjing University School of Medicine and informed consent was obtained from the patients. Peritoneal fluid samples from 20 normal control groups were collected from December 2016 to August ...

Embodiment 2

[0028] The level of IL-23 secretion in ESCs of ectopic foci was analyzed.

[0029] The 10 samples of the control group were obtained from patients who underwent curettage for "menstrual disorders" at the Drum Tower Hospital Affiliated to Nanjing University School of Medicine from December 2016 to August 2017. 5 cases; 10 cases of ectopic lesions were obtained from patients with III-IV endometriosis who underwent laparoscopic ovarian endometrioid cystectomy at the same time, and the nature of ovarian endometrioid cysts was confirmed by pathology after surgery. The two groups of patients were between 22 and 40 years old, had regular menstrual cycles, biphasic basal body temperature, and no other medical or gynecological complications. They did not take hormone drugs 3 months before the operation.

[0030] During the operation, the tissues of the control group or ectopic focus were collected, placed in DMEM-F12 culture medium under aseptic conditions, and stored on ice. ESC (endo...

Embodiment 3

[0033] Construction of EMS mouse model.

[0034] Specifically: select healthy 7-week-old female C57B / L6 mice (Shanghai Shrek Experimental Animal Co., Ltd.), induce with intramuscular injection of estrogen once a week before the operation, take out the uterus of the donor mouse, and cut it into pieces <1mm Tissue fragments, the shredded uterine tissue was injected into recipient mice (uterine fragments of one donor mouse were divided into two and injected into two test mice). The day of modeling was D0, and intraperitoneal injection of IL-23 neutralizing antibody (anti-IL-23, purchased from R&D Company) or control PBS (pH =7.2±0.1).

[0035] Wherein, the IL-23 neutralizing antibody injected above is mouse-derived IL-23p19 antibody, prepared according to the instructions with phosphate buffered saline PBS (pH=7.2±0.1) containing 10% (V / V) fetal bovine serum. Store at an initial concentration of 1 mg / ml, and continue diluting to the working concentration with phosphate buffer s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an interleukin 23 neutralizing antibody (anti-1L-23) in preparation of a drug for endometriosis. Particularly, the interleukin 23 neutralizing antibody can be used for enhancing killing activity of local endometriotic tissue NK cells, inhibiting ectopic endometrium from immune escape and restraining an ectopic focus from growth so as to play a part in treating the endometriosis. By the application of the invention, the application range of the interleukin 23 neutralizing antibody (anti-1L-23) is broadened, and meanwhile, a new direction is provided for the drug therapy for the endometriosis; seen from the results of pharmacodynamic experiments, the the drug from the interleukin 23 neutralizing antibody has a very good effect on the treatment of the endometriosis, and a new method or a new thought is provided for clinic treatment of the endometriosis.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to interleukin 23 neutralizing antibody (anti-Interleukin23, anti-IL-23), in particular to the preparation of interleukin 23 neutralizing antibody (anti-IL-23) in endometrium Application in Atopy Drugs. Background technique [0002] Endometriosis (referred to as endometriosis, Endometriosis, EMS) is a common gynecological disease, manifested by the appearance of endometrium in other parts (such as ovary, peritoneum, etc.) outside the uterine cavity. Under the influence of changes in ovarian hormones, ectopic endometrial tissue undergoes periodic bleeding, accompanied by proliferation of surrounding fibrous tissue and formation of adhesions, and then forms ectopic lesions of endometriosis (abbreviated as ectopic lesions). According to WHO statistics, the number of EMS patients in the world exceeds 176 million, and the incidence rate among women of childbearing age is about 10% to 15%....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61P15/00
CPCA61K2039/505A61P15/00C07K16/244
Inventor 梅洁孙海翔颜桂军
Owner NANJING DRUM TOWER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com